Kodak Set To Emerge From Chapter 11

Editor - 24th January 2013

Posted on Categories Off The PressTags , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Since filing for Chapter 11 Bankruptcy all but a year ago and selling off its portfolio of more than 1000 digital imaging patents just last month, the future for Kodak has looked fairly bleak and the topic of much discussion across our, and other industries.

Today though, Kodak has some good news to report.

U.S. Bankruptcy Court Judge Allan Gropper (Southern District of New York) approved Kodak’s $844 million financing led by Centerbridge Partners LP.

The passing hinged largely on the sale of Kodak’s substatial DI portfolio, which was ultimately sold for $525m to a host of tech giants including Microsoft, Google, Apple, RIM, Facebook, HTC, Adobe, Amazon, and Samsung.

The new players in DI (in the mobile world) will all have access to the technology in some way.

CEO and Chairman Antonio Perez said in prepared statement…

The Court’s approval of this financing commitment puts Kodak in a strong position to emerge from Chapter 11. This agreement, in conjunction with the recently approved sale and licensing of our digital imaging patent portfolio, lays the financial foundation for our Plan of Reorganization and a successful emergence from Chapter 11 as a profitable and sustainable company. Taken together, these accomplishments, along with other recent developments, such as the resolution of certain of our legacy liabilities, demonstrate the tangible and meaningful progress Kodak is making as it moves through the final phase of its restructuring.

Of the $843.7 million in financing, Kodak says $640 million will be rolled over to help finance Kodak’s exit from Chapter 11 Bankruptcy. Some of the money will also go towards paying off an earlier bankruptcy loan from lenders like JPMorgan Chase & Co. and GSO Capital Partners for $950 million.

Full Statement below…

Kodak Receives Court Approval of Financing Agreement

Court’s Decision is Major Step toward Emergence

ROCHESTER, N.Y. In a significant step toward its emergence from Chapter 11, Eastman Kodak Company today received approval from U.S. Bankruptcy Court Judge Allan Gropper of the Southern District of New York for the company’s previously announced commitment from the Steering Committee of the Second Lien Note holders Committee for interim and exit financing. This financing, which authorizes Kodak to borrow up to $844 million, strengthens Kodak’s position to successfully execute its remaining reorganization objectives, finalize its Plan of Reorganization, and emerge from Chapter 11 in mid-2013.

“Taken together, these accomplishments, along with other recent developments, such as the resolution of certain of our legacy liabilities, demonstrate the tangible and meaningful progress Kodak is making as it moves through the final phase of its restructuring.”

“The Court’s approval of this financing commitment puts Kodak in a strong position to emerge from Chapter 11. This agreement, in conjunction with the recently approved sale and licensing of our digital imaging patent portfolio, lays the financial foundation for our Plan of Reorganization and a successful emergence from Chapter 11 as a profitable and sustainable company,” said Antonio M. Perez, Chairman and Chief Executive Officer. “Taken together, these accomplishments, along with other recent developments, such as the resolution of certain of our legacy liabilities, demonstrate the tangible and meaningful progress Kodak is making as it moves through the final phase of its restructuring.”

The previously announced financing includes new money term loans of $455 million, as well as term loans of up to $375 million issued to holders of senior secured notes participating in the new money term loans in a dollar-for-dollar exchange for amounts outstanding under the company’s pre-petition second lien notes. The financing is predicated on certain conditions, including the successful completion of the sale of Kodak’s digital imaging patent portfolio for no less than $500 million. The Bankruptcy Court recently approved the sale of this portfolio for $527 million, and the completion of this sale is expected in February 2013.

Upon meeting certain additional conditions, the approved financing also provides Kodak the option of converting up to $644 million of the loans into exit financing due five years after emergence. The additional conditions include the consummation of a Plan of Reorganization by September 30, 2013, the resolution of the company’s U.K. pension obligations, and the successful completion of all or a portion of the sales of Kodak’s Document Imaging and Personalized Imaging businesses, as detailed in the agreement. Kodak continues to make progress toward these objectives.

CAUTIONARY STATEMENT PURSUANT TO SAFE HARBOR PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This document includes “forward-looking statements” as that term is defined under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning the Company’s plans, objectives, goals, strategies, future events, future revenue or performance, capital expenditures, financing needs, plans or business trends, and other information that is not historical information. When used in this document, the words “estimates,” “expects,” “anticipates,” “projects,” “plans,” “intends,” “believes,” “forecasts,” or future or conditional verbs, such as “will,” “should,” “could,” or “may,” and variations of such words or similar expressions are intended to identify forward-looking statements. All forward-looking statements, including, without limitation, management’s examination of historical operating trends and data are based upon the Company’s expectations and various assumptions. Future events or results may differ from those anticipated or expressed in these forward-looking statements. Important factors that could cause actual events or results to differ materially from these forward-looking statements include, among others, the risks and uncertainties described under the heading “Risk Factors” in the Company’s most recent annual report on Form 10-K under Item 1A of Part 1, in the Company’s most recent quarterly report on Form 10-Q under Item 1A of Part II and those described in filings made by the Company with the U.S. Bankruptcy Court for the Southern District of New York and in other filings the Company makes with the SEC from time to time, as well as the following: the Company’s ability to successfully emerge from chapter 11 as a profitable sustainable company, the ability of the Company to continue as a going concern, the Company’s ability to obtain Bankruptcy Court approval with respect to motions in the chapter 11 cases, the ability of the Company and its subsidiaries to prosecute, develop and consummate one or more plans of reorganization with respect to the chapter 11 cases, Bankruptcy Court rulings in the chapter 11 cases and the outcome of the cases in general, the length of time the Company will operate under the chapter 11 cases, risks associated with third party motions in the chapter 11 cases, which may interfere with the Company’s ability to develop and consummate one or more plans of reorganization once such plans are developed, the potential adverse effects of the chapter 11 proceedings on the Company’s liquidity, results of operations, brand or business prospects, the ability to execute the Company’s business and restructuring plan, increased legal costs related to the Bankruptcy Filing and other litigation, our ability to raise sufficient proceeds from the sale of non-core assets and the monetization of our digital imaging patent portfolios within our plan, the Company’s ability to generate or raise cash and maintain a cash balance sufficient to fund continued investments, capital needs, restructuring payments and service its debt and financing arrangements, the Company’s ability to manage contracts that are critical to its operation, to obtain and maintain appropriate terms with customers, suppliers and service providers, to maintain product reliability and quality, to effectively anticipate technology trends and develop and market new products, solutions and technologies, to retain key executives, managers and employees, our ability to successfully license and enforce our intellectual property rights and the ability of the Company’s non-U.S. subsidiaries to continue to operate their businesses in the normal course and without court supervision. There may be other factors that may cause the Company’s actual results to differ materially from the forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf apply only as of the date of this document and are expressly qualified in their entirety by the cautionary statements included in this report. The Company undertakes no obligation to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events.

 

 

236 thoughts on “Kodak Set To Emerge From Chapter 11”

  1. Pingback: dramamine 50mg nz
  2. Pingback: depakote coupon
  3. Pingback: cialis myths
  4. Pingback: coumadin 5mg usa
  5. Pingback: compazine otc
  6. Pingback: cialis
  7. Pingback: order coreg
  8. Pingback: colchicine online
  9. Pingback: sildenafil dosing
  10. Pingback: how to buy clomid
  11. Pingback: cleocin coupon
  12. Pingback: essay help
  13. Pingback: assignment helper
  14. Pingback: cheap essays
  15. Pingback: essay buy
  16. Pingback: sildenafil viagra
  17. Pingback: generic cialis
  18. Pingback: au cialis
  19. Pingback: installment loans
  20. Pingback: buy cialis
  21. Pingback: play casino
  22. Pingback: real online casino
  23. Pingback: casino slots
  24. Pingback: rxtrust pharm
  25. Pingback: free slots
  26. Pingback: casino game
  27. Pingback: RxTrustPharm
  28. Pingback: cost of cipro
  29. Pingback: ceclor tablet
  30. Pingback: tadalafil 20mg
  31. Pingback: rxtrustpharm.com
  32. Pingback: buy baclofen 10 mg
  33. Pingback: order atarax 25 mg
  34. Pingback: viagra generic
  35. Pingback: buy amaryl 4 mg
  36. Pingback: allegra 180 mg usa
  37. Pingback: cialis online
  38. Pingback: Cialis 40 mg cheap
  39. Pingback: Cialis 20mg prices
  40. Pingback: cialis 20mg
  41. Pingback: Cialis 80mg cheap
  42. Pingback: Cialis 20mg otc
  43. Pingback: https://mymvrc.org
  44. Pingback: viagra online
  45. Pingback: Viagra 150mg pills
  46. Pingback: Viagra 100mg otc
  47. Pingback: cialis 20 mg
  48. Pingback: real casino
  49. Pingback: viagra connect
  50. Pingback: tadalafil cost
  51. Pingback: buy viagra cheap
  52. Pingback: generic for viagra
  53. Pingback: online slots
  54. Pingback: rivers casino
  55. Pingback: herbal viagra
  56. Pingback: generic for cialis
  57. Pingback: cialis to buy
  58. Pingback: cialis generic
  59. Pingback: best-casinos-usa
  60. Pingback: cialis internet
  61. Pingback: davidrer
  62. Pingback: generic for cialis
  63. Pingback: 20 cialis
  64. Pingback: viagra pills
  65. Pingback: cash payday
  66. Pingback: installment loans
  67. Pingback: viagra pills
  68. Pingback: buy levitra online
  69. Pingback: vardenafil 20 mg
  70. Pingback: generic vardenafil
  71. Pingback: Viagra or cialis
  72. Pingback: order cialis
  73. Pingback: mens ed pills
  74. Pingback: cheapest ed pills
  75. Pingback: viagra generic
  76. Pingback: viagra for sale
  77. Pingback: cialis cost
  78. Pingback: cialis
  79. Pingback: buy ciprofloxacin
  80. Pingback: online viagra
  81. Pingback: canadian cialis
  82. Pingback: cialis pill
  83. Pingback: viagra online us

Leave a Reply